title: What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?
authors.affiliation: pea.federico@aoud.sanita.fvg.it.
authors.forename: Federico
authors.initials: F
authors.lastname: Pea
authors.forename: Mario
authors.initials: M
authors.lastname: Furlanut
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Viale
mesh_terms: D000284:Administration, Oral; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D019540:Area Under Curve; D004334:Drug Administration Schedule; D018565:Food-Drug Interactions; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D014230:Triazoles / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics
chemical_list: D000935:Antifungal Agents; D014230:Triazoles; C101425:posaconazole